Integer (NYSE:ITGR) Given New $140.00 Price Target at Benchmark

Integer (NYSE:ITGR) had its price target reduced by Benchmark from $150.00 to $140.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

Other research analysts have also issued reports about the stock. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Truist Financial reduced their price objective on Integer from $163.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Raymond James started coverage on Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 target price for the company. Finally, KeyCorp reduced their price target on Integer from $154.00 to $145.00 and set an “overweight” rating on the stock in a report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Integer presently has an average rating of “Moderate Buy” and a consensus target price of $145.56.

Integer Stock Performance

NYSE ITGR opened at $123.39 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The stock’s 50 day simple moving average is $119.58 and its 200-day simple moving average is $130.26. The company has a market cap of $4.31 billion, a PE ratio of 36.72, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. Integer has a 1-year low of $104.93 and a 1-year high of $146.36.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $437.39 million for the quarter, compared to analysts’ expectations of $428.51 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. As a group, equities research analysts anticipate that Integer will post 6.01 EPS for the current fiscal year.

Institutional Trading of Integer

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bessemer Group Inc. increased its position in shares of Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 125 shares during the last quarter. Yorktown Management & Research Co Inc purchased a new stake in Integer in the first quarter valued at approximately $277,000. LVZ Inc. lifted its stake in Integer by 7.9% during the first quarter. LVZ Inc. now owns 2,830 shares of the medical equipment provider’s stock worth $334,000 after purchasing an additional 207 shares in the last quarter. North Growth Management Ltd. lifted its stake in Integer by 1.0% during the first quarter. North Growth Management Ltd. now owns 98,000 shares of the medical equipment provider’s stock worth $11,510,000 after purchasing an additional 1,000 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its position in shares of Integer by 1.0% during the first quarter. QRG Capital Management Inc. now owns 37,306 shares of the medical equipment provider’s stock worth $4,402,000 after buying an additional 368 shares during the period. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.